Marshall Wace
ENGN icon

Marshall Wace’s enGene Therapeutics ENGN Stock Holding History

Marshall Wace’s Portfolio ENGN Stock Details ENGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-343,928
Closed -$2.34M – 3313
2026
Q1 		$2.34M Hold
343,928
– – ﹤0.01% 1697
2025
Q4 		$3.11M Hold
343,928
– – ﹤0.01% 1372
2025
Q3 		$2.35M Hold
343,928
– – ﹤0.01% 1535
2025
Q2 		$1.25M Sell
343,928
-1,469
-0.4% -$5.51K ﹤0.01% 1763
2025
Q1 		$1.55M Sell
345,397
-248,345
-42% -$1.54M ﹤0.01% 1584
2024
Q4 		$3.95M Sell
593,742
-87,803
-13% -$682K ﹤0.01% 1169
2024
Q3 		$4.5M Sell
681,545
-83,100
-11% -$618K 0.01% 1036
2024
Q2 		$7.21M Sell
764,645
-35,355
-4% -$454K 0.01% 861
2024
Q1 		$13.6M Buy
+800,000
New +$9.79M 0.02% 643

Other funds holding ENGN

FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
PLC
Peapod Lane Capital Bedford Hills, New York $148M AUM 89.92% 1-Year Est. Return

Marshall Wace's ENGN Position: Q2 2026 in Review

Marshall Wace sold out of enGene Therapeutics (ENGN) in Q2 2026, closing a stake of 343,928 shares — an estimated $2.34M sold.

Marshall Wace first reported a position in ENGN in Q1 2024 and held it in 9 quarters. The position peaked at $13.6M in Q1 2024. 60 funds tracked by Wall St. Rank hold ENGN as of Q2 2026.

  • Marshall Wace reported no remaining enGene Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Marshall Wace sold 343,928 enGene Therapeutics shares in Q2 2026, an estimated $2.34M.
  • Marshall Wace first reported a position in enGene Therapeutics in Q1 2024 and held it in 9 quarters.
  • Marshall Wace's enGene Therapeutics position peaked at $13.6M in Q1 2024.
  • 60 funds tracked by Wall St. Rank held enGene Therapeutics as of Q2 2026.

Based on Marshall Wace's 13F filing for Q2 2026, filed 13 Aug 2026.